Press release
Moderate to Severe Psoriasis Market Growth, Trends, Consumer Demand and Key Opportunities
Moderate to Severe Psoriasis Market
Psoriasis is a chronic, immune-mediated skin disorder marked by red, scaly plaques that can cause significant physical discomfort and psychological burden. Among the different types, moderate to severe psoriasis requires systemic therapy or biologics due to its extensive nature and comorbidities, such as psoriatic arthritis, cardiovascular disease, and metabolic syndrome.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71343
Historically, management involved topical corticosteroids, phototherapy, and systemic drugs like methotrexate or cyclosporine. The treatment paradigm, however, has shifted dramatically with the approval of biologics, targeted oral small molecules (JAK/TYK2 inhibitors), and biosimilars, reshaping disease outcomes and accessibility. With advances in precision medicine, digital dermatology, and patient advocacy, the global market is projected to expand significantly through 2034.
Market Overview
• Market Size 2024: USD 17 billion
• Forecast 2034: USD 38 billion
• CAGR (2025-2034): 8%
The market for moderate to severe psoriasis is set for robust growth, supported by the increasing adoption of IL-17 and IL-23 biologics, TYK2 inhibitors, biosimilar launches, and patient-centric treatment models. Expanding healthcare infrastructure in emerging regions further strengthens long-term growth prospects.
Leading Players include: AbbVie, Novartis, Eli Lilly, Johnson & Johnson, Amgen, Pfizer, Bristol Myers Squibb, UCB, and Sun Pharma.
Segmentation Analysis
By Product
• Biologics (TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors, IL-12/23 inhibitors)
• Small Molecules (JAK inhibitors, TYK2 inhibitors)
• Conventional Systemics (Methotrexate, Cyclosporine, Acitretin)
• Topical Agents (used as adjunctive care)
• Biosimilars
• Supportive Care Medications
By Platform
• Hospital Pharmacies
• Specialty Pharmacies
• Online Pharmacies
By Technology
• Biologic & Biosimilar Development Platforms
• Small Molecule Innovation (JAK/TYK2 inhibitors)
• Digital Dermatology & AI Skin Monitoring Tools
• Biomarker & Precision Medicine Diagnostics
By End Use
• Hospitals & Dermatology Clinics
• Specialty Immunology Centers
• Academic & Research Institutes
• Homecare Settings
By Application
• Plaque Psoriasis
• Psoriatic Arthritis with Skin Involvement
• Other Severe Psoriasis Variants
Summary:
Biologics dominate the landscape, particularly IL-17 and IL-23 inhibitors, while TYK2 inhibitors (e.g., deucravacitinib) are the fastest-growing oral therapy class. Biosimilars are lowering treatment costs and expanding patient access, especially in Europe and Asia.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71343/moderate-to-severe-psoriasis-market
Regional Analysis
North America
• Largest market with high biologic penetration, FDA approvals of TYK2 inhibitors, and robust reimbursement frameworks.
• U.S. leads in adoption of IL-23 biologics and digital dermatology platforms.
Europe
• Strong presence with EMA-approved biologics and biosimilars, government reimbursement systems, and patient registries.
• Germany, France, and the UK drive regional market expansion.
Asia-Pacific
• Fastest-growing region due to increasing prevalence of psoriasis, rising healthcare investments, and biosimilar launches in China, India, and Japan.
Middle East & Africa
• Gradual growth with expanding dermatology centers but limited biologic access due to affordability barriers.
Latin America
• Moderate growth, led by Brazil and Mexico, with improving access to biologics and biosimilars.
Regional Summary:
North America and Europe dominate the global market, while Asia-Pacific is projected to post the fastest CAGR through 2034, supported by rising awareness, growing healthcare access, and biosimilar affordability.
Market Dynamics
Key Growth Drivers
• Rising global prevalence of psoriasis and comorbidities.
• Expanding adoption of biologics, JAK inhibitors, and TYK2 inhibitors.
• Biosimilar launches improving affordability and access.
• Growth of AI-powered dermatology and digital monitoring solutions.
Key Challenges
• High treatment costs of biologics and novel small molecules.
• Variable patient response and adherence challenges.
• Underdiagnosis and limited access in low-resource settings.
Latest Trends
• FDA/EMA approvals of next-generation IL-23 inhibitors and TYK2 inhibitors.
• Rapid expansion of biosimilars in Europe and Asia.
• Adoption of teledermatology and AI-based monitoring apps.
• Combination therapy trials to enhance efficacy and durability.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71343
Competitor Analysis
Major Players in the Market:
• AbbVie - Market leader with Humira (adalimumab) and Skyrizi (IL-23 inhibitor).
• Novartis - Strong with Cosentyx (IL-17 inhibitor).
• Eli Lilly - Leading with Taltz (IL-17 inhibitor).
• Johnson & Johnson - Tremfya (IL-23 inhibitor) and Stelara (IL-12/23 inhibitor).
• Amgen - Expanding in biosimilars and biologics.
• Pfizer - Strong JAK/TYK2 inhibitor pipeline.
• Bristol Myers Squibb - Innovator with deucravacitinib (TYK2 inhibitor).
• UCB - Dermatology-focused biologics pipeline.
• Sun Pharma - Expanding generics and biosimilars in dermatology.
Competitive Dynamics:
The market is innovation-driven, with AbbVie, Novartis, and Eli Lilly dominating biologics, while BMS and Pfizer push innovation in TYK2 and JAK inhibitors. Biosimilars are intensifying competition globally, particularly in Europe and Asia-Pacific.
Conclusion
The moderate to severe psoriasis market is evolving rapidly as biologics, small molecules, and biosimilars reshape dermatology care. Despite affordability and access challenges, the long-term outlook through 2034 is highly positive.
Key Takeaways:
• Market expected to grow at a CAGR of 8% (2025-2034).
• IL-17 and IL-23 inhibitors dominate, while TYK2 inhibitors are the fastest-growing segment.
• North America and Europe lead adoption, while Asia-Pacific posts fastest growth.
• Biosimilars and digital dermatology tools expand access and affordability.
• Competition centers on biologics innovation, biosimilar strategies, and precision dermatology solutions.
Overall, the moderate to severe psoriasis market offers significant opportunities for global pharma leaders, biotech innovators, and digital health providers to advance treatment and improve patient outcomes worldwide.
This report is also available in the following languages : Japanese (中等度から重度の乾癬市場), Korean (중등도에서 중증 건선 시장), Chinese (中度至重度牛皮癣市场), French (Marché du psoriasis modéré à sévère), German (Markt für mittelschwere bis schwere Psoriasis), and Italian (Mercato della psoriasi da moderata a grave), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @https://exactitudeconsultancy.com/reports/71343/moderate-to-severe-psoriasis-market#request-a-sample
Our More Reports:
Cutaneous Squamous cell Carcinoma Market
https://exactitudeconsultancy.com/reports/71380/cutaneous-squamous-cell-carcinoma-market
Dystrophic Epidermolysis Bullosa Market
https://exactitudeconsultancy.com/reports/71382/dystrophic-epidermolysis-bullosa-market
Generalized Pustular Psoriasis Market
https://exactitudeconsultancy.com/reports/71384/generalized-pustular-psoriasis-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Moderate to Severe Psoriasis Market Growth, Trends, Consumer Demand and Key Opportunities here
News-ID: 4163673 • Views: …
More Releases from Exactitude Consultancy
Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Market Massive …
Introduction
Systemic sclerosis (scleroderma) is a rare autoimmune disease characterized by fibrosis of the skin and internal organs, vascular damage, and immune system dysfunction. Among its most serious complications is systemic sclerosis-associated interstitial lung disease (SSc-ILD), a progressive and potentially fatal condition that significantly reduces quality of life and survival rates.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71331
Historically, treatment relied on immunosuppressants such as cyclophosphamide and mycophenolate mofetil, but…
Hemophagocytic Lymphohistiocytosis (HLH) Market to Reach USD 1.2 Billion by 2034
Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening syndrome of excessive immune activation characterized by fever, hepatosplenomegaly, cytopenias, hyperferritinemia, and organ dysfunction. HLH can be primary (familial, genetic) or secondary (triggered by infections, malignancies, or autoimmune conditions).
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71319
Historically, treatment relied on immunosuppressive agents such as dexamethasone and etoposide, but survival outcomes remained poor. Recent advances in stem cell transplantation, targeted biologics (e.g., emapalumab,…
Hashimoto's Thyroiditis Market to Reach USD 9 Billion by 2034
Hashimoto's thyroiditis, also known as chronic lymphocytic thyroiditis, is the most common autoimmune thyroid disorder and a leading cause of hypothyroidism worldwide. It occurs when the immune system attacks the thyroid gland, leading to inflammation, gradual loss of thyroid function, and symptoms such as fatigue, weight gain, and sensitivity to cold.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71317
Although lifelong thyroid hormone replacement therapy (levothyroxine) remains the standard treatment,…
Arthralgia Market Growth, Applications, Innovations and Business Outlook by 2034
Introduction
Arthralgia, or joint pain, is a common clinical symptom associated with a wide range of conditions, including osteoarthritis, rheumatoid arthritis, lupus, infections, and injury-related disorders. While not a disease itself, arthralgia significantly impacts patient quality of life and is one of the leading reasons for clinical visits globally.
Download Full PDF Sample Copy of Market Report @https://exactitudeconsultancy.com/request-sample/71333
Historically managed with analgesics, NSAIDs, and corticosteroids, the treatment landscape is evolving with the expansion…
More Releases for TYK2
Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline 2025: FDA Updates, Therapy Innovati …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Tyrosine Kinase 2 (TYK2) Inhibitors pipeline constitutes 15+ key companies continuously working towards developing 15+ Tyrosine Kinase 2 (TYK2) Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical…
Emerging Trends Influencing The Growth Of The Kinase Inhibitors Market: Advances …
The Kinase Inhibitors Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
How Big Is the Kinase Inhibitors Market Size Expected to Be by 2034?
The kinase inhibitors market will grow from $62.75 billion in 2024 to $67.57 billion in 2025, reflecting a CAGR of 7.7%. Growth…
TYK2 Kinase Inhibitors Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, …
(Albany, USA) "TYK2 Kinase Inhibitors Pipeline Insight, 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the TYK2 Kinase Inhibitors Therapeutics Market.
As per DelveInsight's assessment, about 15+ prominent pharma and biotech giants are working on 15+ drugs in the TYK2 Kinase Inhibitors pipeline landscape globally.
The TYK2 Kinase Inhibitors pipeline report provides a detailed description of the pipeline drugs, including the mechanism…
Key Trends Shaping the Future Kinase Inhibitors Market From 2025-2034: Advances …
What Is the Estimated Market Size and Growth Rate for the Kinase Inhibitors Market?
In the past few years, there has been a significant increase in the market size of kinase inhibitors. This market is set to expand from $62.75 billion in 2024 to $67.57 billion in 2025, marking a compound annual growth rate (CAGR) of 7.7%. The historical growth can be linked to numerous factors including the rise in cancer…
Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline Assessment, 2023 Updates | In-depth …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Tyrosine Kinase 2 (TYK2) Inhibitors pipeline constitutes 15+ key companies continuously working towards developing 15+ Tyrosine Kinase 2 (TYK2) Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and…
Non Receptor Tyrosine Protein Kinase TYK2 Market Share Will Gain Hugh Momentum b …
In recent years, the Global Non Receptor Tyrosine Protein Kinase TYK2 Market has witnessed significant growth and is expected to continue to do so during the forecast period 2023-2030. This report aims to provide a comprehensive analysis of the market's critical aspects, including its strengths, weaknesses, opportunities, and threats. With the help of SWOT and Porter's Five Forces analysis, we will explore the different players operating in the market and…
